furosemide has been researched along with Kidney Failure in 48 studies
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.
furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.
Kidney Failure: A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We attempted to identify the difference in diuretic properties between tolvaptan (TLV) and furosemide (FUR) in congestive heart failure (CHF) patients with loop diuretic resistance and renal impairment." | 9.30 | Different diuretic properties between tolvaptan and furosemide in congestive heart failure patients with diuretic resistance and renal impairment: a subanalysis of the K-STAR. ( Ako, J; Ikeda, Y; Inomata, T; Izumi, T; Kida, K; Sato, N; Shibagaki, Y, 2019) |
| "The Answering question on tolvaptan's efficacy for patients with acute decompensated heart failure and renal failure (AQUAMARINE) is a multicenter, randomized controlled clinical trial, which will enroll 220 patients from 17 hospitals in Japan." | 9.19 | Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study. ( Fujii, H; Matsue, Y; Nagahori, W; Nishioka, T; Noda, M; Okishige, K; Onishi, Y; Ono, Y; Sakurada, H; Satoh, Y; Sugi, K; Suzuki, M; Takahashi, A; Tejima, T; Torii, S; Yamaguchi, S; Yoshida, K, 2014) |
| "In a subset analysis of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan trial, 759 patients (18% of total) had elevated blood urea nitrogen (BUN) (> 20 mg/dl) and low SBP (<105 mmHg) at admission." | 9.16 | Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. ( Blair, J; Burnett, JC; Gheorghiade, M; Grinfeld, L; Konstam, MA; Krasa, HB; Maggioni, AP; Ouyang, J; Pang, PS; Swedberg, K; Vaduganathan, M; Zannad, F; Zimmer, C, 2012) |
| " furosemide for diuretic-resistant CHF patients led to a better renal safety profile and improved clinical endpoints such as mortality and heart failure-related hospitalizations." | 8.91 | Hypertonic saline plus i.v. furosemide improve renal safety profile and clinical outcomes in acute decompensated heart failure: A meta-analysis of the literature. ( Ariano, C; Cantatrione, S; De Vecchis, R; Esposito, C, 2015) |
| "Currently, there are no meta-analyses evaluating the efficacy and safety of intermittent vs continuous furosemide for heart failure concomitant renal dysfunction." | 8.02 | Efficacy and safety of intermittent vs continuous furosemide for heart failure concomitant renal dysfunction: A protocol for systematic review and meta-analysis. ( Chen, S; Lin, Y; Zhou, C; Zhou, M, 2021) |
| "Although tolvaptan is a recently approved drug for heart failure and causes aquaresis without affecting renal function, its clinical efficacy for patients with acute decompensated heart failure (ADHF) is yet to be elucidated." | 7.79 | Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population. ( Hashimoto, Y; Iwatsuka, R; Matsue, Y; Matsumura, A; Mizukami, A; Nagahori, W; Ohno, M; Seya, M; Suzuki, M, 2013) |
| "Clinical data are scarce for furosemide administered as a low-dose (<160 mg/24 hours) continuous intravenous infusion in acute heart failure (HF)." | 7.78 | Clinical experience with low-dose continuous infusion of furosemide in acute heart failure: assessment of efficacy and safety. ( Chan, CY; Elkayam, U; Hshieh, S; Ng, TM, 2012) |
| "The purpose of this economic analysis was to develop an economic model using intra-institutional cost data for acute, oliguric renal insufficiency treated with either an albumin-furosemide complex or albumin followed by furosemide (sequential therapy)." | 7.70 | Pharmacoeconomic comparison of an albumin-furosemide complex versus sequential therapy for renal insufficiency. ( Erstad, BL, 1999) |
| "Loop diuretics used in the treatment of heart failure often induce renal impairment." | 6.82 | Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure. ( Hasegawa, T; Ikeda, U; Izawa, A; Kimura, K; Misawa, T; Momose, T; Morita, T; Motoki, H, 2016) |
| "Lacidipine was not very effective in controlling blood pressure and had an adverse effect on renal function." | 6.68 | Effect of lacidipine, a dihydropyridine calcium antagonist on renal function of hypertensive patients with renal insufficiency. ( Bailey, RR; Lynn, KL; Robson, RA; Shand, BI; Smith, AH, 1997) |
| "The combined prophylactic strategy of sodium bicarbonate plus N-acetylsyteine (NAC) seems to be effective in preventing contrast induced acute kidney injury (CI-AKI) in patients at low-to-medium risk." | 6.25 | Renal insufficiency following contrast media administration trial II (REMEDIAL II): RenalGuard system in high-risk patients for contrast-induced acute kidney injury: rationale and design. ( Briguori, C; Condorelli, G; Ricciardelli, B; Visconti, G, 2011) |
| "We attempted to identify the difference in diuretic properties between tolvaptan (TLV) and furosemide (FUR) in congestive heart failure (CHF) patients with loop diuretic resistance and renal impairment." | 5.30 | Different diuretic properties between tolvaptan and furosemide in congestive heart failure patients with diuretic resistance and renal impairment: a subanalysis of the K-STAR. ( Ako, J; Ikeda, Y; Inomata, T; Izumi, T; Kida, K; Sato, N; Shibagaki, Y, 2019) |
| "The Answering question on tolvaptan's efficacy for patients with acute decompensated heart failure and renal failure (AQUAMARINE) is a multicenter, randomized controlled clinical trial, which will enroll 220 patients from 17 hospitals in Japan." | 5.19 | Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study. ( Fujii, H; Matsue, Y; Nagahori, W; Nishioka, T; Noda, M; Okishige, K; Onishi, Y; Ono, Y; Sakurada, H; Satoh, Y; Sugi, K; Suzuki, M; Takahashi, A; Tejima, T; Torii, S; Yamaguchi, S; Yoshida, K, 2014) |
| "We examined diuretic response (defined as Δ weight kg/40 mg furosemide) in 1745 hospitalized acute heart failure patients from the PROTECT trial." | 5.19 | Diuretic response in acute heart failure: clinical characteristics and prognostic significance. ( Bloomfield, DM; Cleland, JG; Cotter, G; Damman, K; Davison, B; Dittrich, HC; Fiuzat, M; Givertz, MM; Hillege, HL; Massie, BM; Metra, M; O'Connor, CM; Ponikowski, P; Teerlink, JR; Valente, MA; Van Veldhuisen, DJ; Voors, AA, 2014) |
| "In a subset analysis of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan trial, 759 patients (18% of total) had elevated blood urea nitrogen (BUN) (> 20 mg/dl) and low SBP (<105 mmHg) at admission." | 5.16 | Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. ( Blair, J; Burnett, JC; Gheorghiade, M; Grinfeld, L; Konstam, MA; Krasa, HB; Maggioni, AP; Ouyang, J; Pang, PS; Swedberg, K; Vaduganathan, M; Zannad, F; Zimmer, C, 2012) |
| "RenalGuard therapy is superior to sodium bicarbonate and N-acetylcysteine in preventing contrast-induced acute kidney injury in high-risk patients." | 5.15 | Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury. ( Airoldi, F; Briguori, C; Condorelli, G; Focaccio, A; Golia, B; Ricciardelli, B; Sangiorgi, GM; Valgimigli, M; Visconti, G, 2011) |
| " furosemide for diuretic-resistant CHF patients led to a better renal safety profile and improved clinical endpoints such as mortality and heart failure-related hospitalizations." | 4.91 | Hypertonic saline plus i.v. furosemide improve renal safety profile and clinical outcomes in acute decompensated heart failure: A meta-analysis of the literature. ( Ariano, C; Cantatrione, S; De Vecchis, R; Esposito, C, 2015) |
| " Pivotal and representative studies are discussed relating to the pharmacology, pharmacokinetics, and use of torsemide in patients with congestive heart failure, renal disease, hepatic disease, and hypertension." | 4.79 | Torsemide: a pyridine-sulfonylurea loop diuretic. ( Adams, KF; Blose, JS; Patterson, JH, 1995) |
| "Currently, there are no meta-analyses evaluating the efficacy and safety of intermittent vs continuous furosemide for heart failure concomitant renal dysfunction." | 4.02 | Efficacy and safety of intermittent vs continuous furosemide for heart failure concomitant renal dysfunction: A protocol for systematic review and meta-analysis. ( Chen, S; Lin, Y; Zhou, C; Zhou, M, 2021) |
| "Although tolvaptan is a recently approved drug for heart failure and causes aquaresis without affecting renal function, its clinical efficacy for patients with acute decompensated heart failure (ADHF) is yet to be elucidated." | 3.79 | Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population. ( Hashimoto, Y; Iwatsuka, R; Matsue, Y; Matsumura, A; Mizukami, A; Nagahori, W; Ohno, M; Seya, M; Suzuki, M, 2013) |
| "Clinical data are scarce for furosemide administered as a low-dose (<160 mg/24 hours) continuous intravenous infusion in acute heart failure (HF)." | 3.78 | Clinical experience with low-dose continuous infusion of furosemide in acute heart failure: assessment of efficacy and safety. ( Chan, CY; Elkayam, U; Hshieh, S; Ng, TM, 2012) |
| "We present a case study of a severe episode of iodine toxicity following povidone-iodine wash with clinical manifestations of cardiovascular collapse, metabolic acidosis, renal failure and seizures." | 3.77 | Cardiovascular collapse following povidone-iodine wash. ( Lavee, O; Linderman, R; Mackie, J; Nanavati, Z; Ramaswamykanive, H, 2011) |
| "Hypertension, renal dysfunction and furosemide administration at hospital admission are predictors of WRF among hospitalized patients." | 3.75 | Predictors of "worsening renal function" in patients hospitalized in internal medicine department. ( Al-Jabi, SW; Jayousi, HM; Sawalha, AF; Sweileh, WM; Zyoud, SH, 2009) |
| "The purpose of this economic analysis was to develop an economic model using intra-institutional cost data for acute, oliguric renal insufficiency treated with either an albumin-furosemide complex or albumin followed by furosemide (sequential therapy)." | 3.70 | Pharmacoeconomic comparison of an albumin-furosemide complex versus sequential therapy for renal insufficiency. ( Erstad, BL, 1999) |
| "Loop diuretics used in the treatment of heart failure often induce renal impairment." | 2.82 | Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure. ( Hasegawa, T; Ikeda, U; Izawa, A; Kimura, K; Misawa, T; Momose, T; Morita, T; Motoki, H, 2016) |
| "Intravenous loop diuretics are still the cornerstone of therapy in acute decompensated heart failure, however, the optimal dosage and administration strategies remain poorly defined particularly in patients with an associated renal dysfunction." | 2.80 | Short and long-term effects of continuous versus intermittent loop diuretics treatment in acute heart failure with renal dysfunction. ( Angelini, GD; Beltrami, M; Franci, B; Gonnelli, S; Nuti, R; Palazzuoli, A; Pellegrini, M; Ruocco, G, 2015) |
| "The occurrence of renal failure is associated to an increased death risk." | 2.73 | Hypertonic saline solution for renal failure prevention in patients with decompensated heart failure. ( Azevedo, CH; Bacal, F; Bocchi, EA; Carneiro, RM; Chizzola, PR; Ferreira, SM; Issa, VS; Mangini, S, 2007) |
| " Adverse events occurred in 12 (26." | 2.70 | Evaluation of the safety and efficacy of telmisartan and enalapril, with the potential addition of frusemide, in moderate-renal failure patients with mild-to-moderate hypertension. ( Baumelou, B; Chanard, J; Hannedouche, T, 2001) |
| "Lacidipine was not very effective in controlling blood pressure and had an adverse effect on renal function." | 2.68 | Effect of lacidipine, a dihydropyridine calcium antagonist on renal function of hypertensive patients with renal insufficiency. ( Bailey, RR; Lynn, KL; Robson, RA; Shand, BI; Smith, AH, 1997) |
| "Recently, the Acute Respiratory Distress Syndrome Network Fluid and Catheter Treatment Trial reported that a conservative fluid management strategy, compared with a fluid liberal strategy, increased the mean (+/- SE) number of ventilator-free days in patients with ALI (14." | 2.44 | Nonventilatory treatments for acute lung injury and ARDS. ( Calfee, CS; Matthay, MA, 2007) |
| "Contrast media associated acute renal failure represents the third cause of in-hospital renal function deterioration after decreased renal perfusion and post-operative renal insufficiency." | 2.43 | New pharmacological protocols to prevent or reduce contrast media nephropathy. ( Airoldi, F; Briguori, C; Colombo, A; Morici, N, 2005) |
| "The cardiorenal syndrome is not well understood, and a uniform definition is lacking." | 2.43 | Acute decompensated heart failure: the cardiorenal syndrome. ( Francis, G, 2006) |
| "Patients with diabetic nephropathy develop nephrotic syndrome and may show limited response to conventional therapy." | 1.48 | Tolvaptan alleviates excessive fluid retention of nephrotic diabetic renal failure unresponsive to furosemide. ( Hoshiyama, A; Kamata, Y; Masaki, T; Shichiri, M; Takada, T; Toki, T, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (16.67) | 18.2507 |
| 2000's | 15 (31.25) | 29.6817 |
| 2010's | 23 (47.92) | 24.3611 |
| 2020's | 2 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Ferdaus, MZ | 1 |
| Gratreak, BDK | 1 |
| Miller, L | 1 |
| Si, J | 1 |
| McCormick, JA | 1 |
| Yang, CL | 1 |
| Ellison, DH | 1 |
| Terker, AS | 1 |
| Chen, S | 1 |
| Lin, Y | 1 |
| Zhou, M | 1 |
| Zhou, C | 1 |
| Lewicki, P | 1 |
| Basourakos, SP | 1 |
| Qiu, Y | 1 |
| Arenas-Gallo, C | 1 |
| Scherr, DS | 1 |
| Ponsky, LE | 1 |
| Shoag, JE | 1 |
| Ferrada, P | 1 |
| Takada, T | 1 |
| Masaki, T | 1 |
| Hoshiyama, A | 1 |
| Toki, T | 1 |
| Kamata, Y | 1 |
| Shichiri, M | 1 |
| Ikeda, Y | 1 |
| Inomata, T | 1 |
| Kida, K | 1 |
| Shibagaki, Y | 1 |
| Sato, N | 1 |
| Izumi, T | 1 |
| Ako, J | 1 |
| Llorens, P | 1 |
| Miró, Ò | 1 |
| Herrero, P | 1 |
| Martín-Sánchez, FJ | 1 |
| Jacob, J | 1 |
| Valero, A | 1 |
| Alonso, H | 1 |
| Pérez-Durá, MJ | 1 |
| Noval, A | 1 |
| Gil-Román, JJ | 1 |
| Zapater, P | 1 |
| Llanos, L | 1 |
| Gil, V | 1 |
| Perelló, R | 1 |
| Matsue, Y | 2 |
| Suzuki, M | 2 |
| Nagahori, W | 2 |
| Yoshida, K | 1 |
| Onishi, Y | 1 |
| Satoh, Y | 1 |
| Ono, Y | 1 |
| Nishioka, T | 1 |
| Noda, M | 1 |
| Sugi, K | 1 |
| Torii, S | 1 |
| Tejima, T | 1 |
| Sakurada, H | 1 |
| Yamaguchi, S | 1 |
| Okishige, K | 1 |
| Fujii, H | 1 |
| Takahashi, A | 1 |
| Ferreira, JP | 1 |
| Santos, M | 1 |
| Almeida, S | 1 |
| Marques, I | 1 |
| Bettencourt, P | 1 |
| Carvalho, H | 1 |
| Valente, MA | 1 |
| Voors, AA | 1 |
| Damman, K | 1 |
| Van Veldhuisen, DJ | 1 |
| Massie, BM | 2 |
| O'Connor, CM | 1 |
| Metra, M | 1 |
| Ponikowski, P | 1 |
| Teerlink, JR | 1 |
| Cotter, G | 1 |
| Davison, B | 1 |
| Cleland, JG | 1 |
| Givertz, MM | 2 |
| Bloomfield, DM | 1 |
| Fiuzat, M | 1 |
| Dittrich, HC | 2 |
| Hillege, HL | 1 |
| De Vecchis, R | 2 |
| Esposito, C | 2 |
| Ariano, C | 2 |
| Cantatrione, S | 2 |
| Palazzuoli, A | 1 |
| Pellegrini, M | 1 |
| Franci, B | 1 |
| Beltrami, M | 1 |
| Ruocco, G | 1 |
| Gonnelli, S | 1 |
| Angelini, GD | 1 |
| Nuti, R | 1 |
| Füeßl, HS | 1 |
| Kimura, K | 1 |
| Momose, T | 1 |
| Hasegawa, T | 1 |
| Morita, T | 1 |
| Misawa, T | 1 |
| Motoki, H | 1 |
| Izawa, A | 1 |
| Ikeda, U | 1 |
| Chau, CH | 1 |
| Williams, DO | 1 |
| Sweileh, WM | 1 |
| Sawalha, AF | 1 |
| Jayousi, HM | 1 |
| Zyoud, SH | 1 |
| Al-Jabi, SW | 1 |
| Alim, N | 1 |
| Patel, JY | 1 |
| Ramaswamykanive, H | 1 |
| Nanavati, Z | 1 |
| Mackie, J | 1 |
| Linderman, R | 1 |
| Lavee, O | 1 |
| Briguori, C | 3 |
| Visconti, G | 2 |
| Ricciardelli, B | 2 |
| Condorelli, G | 2 |
| Focaccio, A | 1 |
| Airoldi, F | 2 |
| Valgimigli, M | 1 |
| Sangiorgi, GM | 1 |
| Golia, B | 1 |
| Boissevain, I | 1 |
| Fusco, A | 1 |
| Ciccarelli, A | 1 |
| Cioppa, C | 1 |
| Giasi, A | 1 |
| Ng, TM | 1 |
| Hshieh, S | 1 |
| Chan, CY | 1 |
| Elkayam, U | 1 |
| Vaduganathan, M | 1 |
| Gheorghiade, M | 1 |
| Pang, PS | 1 |
| Konstam, MA | 1 |
| Zannad, F | 1 |
| Swedberg, K | 1 |
| Grinfeld, L | 1 |
| Burnett, JC | 1 |
| Krasa, HB | 1 |
| Zimmer, C | 1 |
| Blair, J | 1 |
| Ouyang, J | 1 |
| Maggioni, AP | 1 |
| Toft, P | 1 |
| Runge Sørensen, C | 1 |
| Madsen, JK | 1 |
| Schmidt, F | 1 |
| Sloth, E | 1 |
| Seya, M | 1 |
| Iwatsuka, R | 1 |
| Mizukami, A | 1 |
| Ohno, M | 1 |
| Matsumura, A | 1 |
| Hashimoto, Y | 1 |
| Maddox, TG | 1 |
| Morici, N | 1 |
| Colombo, A | 1 |
| Luz, C | 1 |
| Souza, A | 1 |
| Reis, R | 1 |
| Fregoneze, JB | 1 |
| de Castro e Silva, E | 1 |
| Francis, G | 1 |
| Calfee, CS | 1 |
| Matthay, MA | 1 |
| Chan, YH | 1 |
| Wong, KM | 1 |
| Kwok, PC | 1 |
| Liu, AY | 1 |
| Choi, KS | 1 |
| Chau, KF | 1 |
| Li, CS | 1 |
| Cioffi, G | 1 |
| Tarantini, L | 1 |
| Pulignano, G | 1 |
| Del Sindaco, D | 1 |
| De Feo, S | 1 |
| Opasich, C | 1 |
| Dilenarda, A | 1 |
| Stefenelli, C | 1 |
| Furlanello, F | 1 |
| Celentano, C | 1 |
| Prefumo, F | 1 |
| di Vera, E | 1 |
| Iannicco, A | 1 |
| Gallo, DP | 1 |
| Liberati, M | 1 |
| Fields, TK | 1 |
| Pearson, LL | 1 |
| Issa, VS | 1 |
| Bacal, F | 1 |
| Mangini, S | 1 |
| Carneiro, RM | 1 |
| Azevedo, CH | 1 |
| Chizzola, PR | 1 |
| Ferreira, SM | 1 |
| Bocchi, EA | 1 |
| Mahesh, B | 1 |
| Yim, B | 1 |
| Robson, D | 1 |
| Pillai, R | 1 |
| Ratnatunga, C | 1 |
| Pigott, D | 1 |
| Blose, JS | 1 |
| Adams, KF | 1 |
| Patterson, JH | 1 |
| Solomon, R | 1 |
| Werner, C | 1 |
| Mann, D | 1 |
| D'Elia, J | 1 |
| Silva, P | 1 |
| Barrett, BJ | 1 |
| Parfrey, PS | 1 |
| Long, GW | 1 |
| Misra, DC | 1 |
| Juleff, R | 1 |
| Blossom, G | 1 |
| Czako, PF | 1 |
| Glover, JL | 1 |
| Abe, K | 1 |
| Ito, S | 1 |
| Bailey, RR | 1 |
| Shand, BI | 1 |
| Smith, AH | 1 |
| Robson, RA | 1 |
| Lynn, KL | 1 |
| Walter, RE | 1 |
| Anderson, RJ | 1 |
| Erstad, BL | 1 |
| Tippins, RB | 1 |
| Torres, WE | 1 |
| Baumgartner, BR | 1 |
| Baumgarten, DA | 1 |
| Hannedouche, T | 1 |
| Chanard, J | 1 |
| Baumelou, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Open-label Study of Dapagliflozin in Patients With or Without Type 2 Diabetes Admitted With Acute Heart Failure[NCT04298229] | Phase 3 | 240 participants (Actual) | Interventional | 2020-04-01 | Completed | ||
| Continuous Versus Intermittent Loop Diuretics Infusion Dosing in Acute Heart Failure: Effects on Renal Function, Outcome and BNP Levels[NCT01441245] | Phase 4 | 57 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Renal Insufficiency Following Contrast Media Administration Trial II (Remedial II): The RenalGuard System in High-Risk Patients for Contrast-Induced Acute Kidney Injury[NCT01098032] | Phase 3 | 294 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Pirfenidone Effect on the Recovery of Renal Function in Patients With Septic Acute Kidney Injury[NCT02530359] | Phase 4 | 90 participants (Anticipated) | Interventional | 2015-10-31 | Not yet recruiting | ||
| Renal Insufficiency Following Contrast Media Administration Trial IV: Contrast Media Volume Control for Limiting Contrast-Induced Acute Kidney in Acute Coronary Syndrome.[NCT04714736] | 522 participants (Anticipated) | Interventional | 2020-02-10 | Recruiting | |||
| Renal Insufficiency Following Contrast Media Administration Trial III (REMEDIAL III): Renalguard System Versus Left-ventricular End-diastolic Pressure-guided Hydration in High-risk Patients for Contrast-induced Acute Kidney Injury[NCT02489669] | 700 participants (Anticipated) | Interventional | 2015-07-15 | Enrolling by invitation | |||
| Clinical Controlled Trial to Determinate the Role of Sodium Bicarbonate in the Prevention of Contrast-Induced Nephropathy in High-Risk Patients Undergoing to Diagnostic Coronariography and/or Percutaneous Coronary Intervention[NCT00424320] | Phase 3 | 100 participants | Interventional | 2006-10-31 | Recruiting | ||
| A Pilot Study for the Efficacy and Safety of Mesenchymal Stem Cell in Acute Severe Respiratory Failure.[NCT02112500] | Phase 2 | 10 participants (Anticipated) | Interventional | 2014-02-28 | Recruiting | ||
| The Effect of Aminophylline on Preventing Acute Kidney Injury in Pediatric Patients Undergoing Open Heart Surgery[NCT03897335] | Phase 3 | 80 participants (Anticipated) | Interventional | 2019-02-07 | Recruiting | ||
| Hypertonic Saline Solution in Decompensated Heart Failure[NCT00555685] | Phase 2 | 34 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Study to Evaluate the Effectiveness of Induced Diuresis With Matched Hydration Therapy Compared to Standard Overnight Hydration in the Prevention of Contrast Induced Nephropathy -MYTHOS Study[NCT00702728] | Phase 3 | 120 participants (Anticipated) | Interventional | 2008-06-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01441245)
Timeframe: participants were followed for the duration of hospital stay, an average of 13 days
| Intervention | pg/mL (Mean) |
|---|---|
| BNP Change in cIV | -525 |
| BNP Change in iIV | -148 |
(NCT01441245)
Timeframe: in-hospital
| Intervention | percentage of partecipants (Number) |
|---|---|
| Dopamine Infusion in cIV | 50 |
| Dopamine Infusion in iIV | 26 |
(NCT01441245)
Timeframe: from admission to discharge, an average of 12 days
| Intervention | pg/ml (Mean) |
|---|---|
| BNP Levels at Discharge in cIV Group | 679 |
| BNP Levels at Discharge in iIV Group | 949 |
this study aimed to evaluate the effects of continuous infusion of furosemide in comparison to twice daily regimens at similar doses with respect to changes in renal function in terms of creatinine levels and GFR, urine output and BNP levels from admission to discharge (NCT01441245)
Timeframe: time period ranging from 72 h to 120 h.
| Intervention | mL (Mean) |
|---|---|
| Urine Output in cIV | 2505 |
| Urine Output in iIV | 2140 |
evaluation of renal function in terms of changes in creatinine levels during hospitalization in the two arms. (NCT01441245)
Timeframe: participants were followed for the duration of hospital stay, an average of 13 days
| Intervention | mg/dL (Mean) |
|---|---|
| Changes in Creatinine in cIV Group | -0.10 |
| Changes in Creatinine in iIV Group | -0.50 |
(NCT01441245)
Timeframe: from admission to discharge, an average of 12 days
| Intervention | (ml/min·1.73 m2) (Mean) |
|---|---|
| GFR Change in cIV | -3.18 |
| GFR Change in iIV | -1.93 |
(NCT01441245)
Timeframe: from admission to discharge, an average of 12 days
| Intervention | mg/dL (Mean) |
|---|---|
| Creatinine at Discharge in cIV | 1.78 |
| Creatinine at Discharge in iIV | 1.51 |
(NCT01441245)
Timeframe: from admission to discharge, an average of 12 days
| Intervention | (ml/min·1.73 m2) (Mean) |
|---|---|
| GFR at Discharge in cIV | 44.8 |
| GFR at Discharge in iIV | 46.7 |
percentage of participants with hospital stay > 10 days (NCT01441245)
Timeframe: in-hospital
| Intervention | percentage of partecipants (Number) |
|---|---|
| Lenght of Hospitalization in cIV | 80 |
| Lenght of Hospitalization in iIV | 44 |
The primary outcome measure will be the rate of development of CI-AKI in the 2 study arms (number of participants). CI-AKI is defined as an increase in the serum creatinine concentration >=0.3 mg/dL from the baseline value at 48 hours after administration of the contrast media or the need for dialysis. (NCT01098032)
Timeframe: at 48 hours following contrast exposure
| Intervention | participants (Number) |
|---|---|
| Systemic Alone Therapy Group | 146 |
| RenalGuard System Group | 146 |
7 reviews available for furosemide and Kidney Failure
| Article | Year |
|---|---|
Hypertonic saline plus i.v. furosemide improve renal safety profile and clinical outcomes in acute decompensated heart failure: A meta-analysis of the literature.
Topics: Comorbidity; Diuretics; Drug Therapy, Combination; Female; Furosemide; Heart Failure; Hospital Morta | 2015 |
Renal insufficiency following contrast media administration trial II (REMEDIAL II): RenalGuard system in high-risk patients for contrast-induced acute kidney injury: rationale and design.
Topics: Acetylcysteine; Acute Kidney Injury; Biomarkers; Chi-Square Distribution; Chronic Disease; Contrast | 2011 |
Adverse reactions to contrast material: recognition, prevention, and treatment.
Topics: Anaphylaxis; Calcium Channel Blockers; Contrast Media; Diuretics; Dose-Response Relationship, Drug; | 2002 |
New pharmacological protocols to prevent or reduce contrast media nephropathy.
Topics: Acetylcysteine; Antioxidants; Ascorbic Acid; Contrast Media; Diuretics; Fluid Therapy; Furosemide; H | 2005 |
Acute decompensated heart failure: the cardiorenal syndrome.
Topics: Acute Disease; Disease Progression; Diuretics; Furosemide; Glomerular Filtration Rate; Heart Failure | 2006 |
Nonventilatory treatments for acute lung injury and ARDS.
Topics: Adrenal Cortex Hormones; Clinical Trials as Topic; Critical Care; Fluid Therapy; Furosemide; Humans; | 2007 |
Torsemide: a pyridine-sulfonylurea loop diuretic.
Topics: Clinical Trials as Topic; Diuretics; Drug Interactions; Furosemide; Heart Failure; Humans; Liver Cir | 1995 |
17 trials available for furosemide and Kidney Failure
| Article | Year |
|---|---|
Different diuretic properties between tolvaptan and furosemide in congestive heart failure patients with diuretic resistance and renal impairment: a subanalysis of the K-STAR.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Biomarkers; Creatinine; Drug Res | 2019 |
Clinical effects and safety of different strategies for administering intravenous diuretics in acutely decompensated heart failure: a randomised clinical trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Biomarkers; Creatinine; Diuretics; Female; Furosemide; Heart | 2014 |
Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study.
Topics: Acute Disease; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Drug Therapy, Com | 2014 |
Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Chronic Disease; Disease Progression; Diuretics; Edema; Fema | 2014 |
Diuretic response in acute heart failure: clinical characteristics and prognostic significance.
Topics: Acute Disease; Aged; Analysis of Variance; Atherosclerosis; Bumetanide; Diabetes Complications; Diur | 2014 |
Short and long-term effects of continuous versus intermittent loop diuretics treatment in acute heart failure with renal dysfunction.
Topics: Acute Disease; Administration, Intravenous; Aged; Diuretics; Female; Furosemide; Heart Failure; Huma | 2015 |
Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure.
Topics: Acute Disease; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics | 2016 |
Renal insufficiency following contrast media administration trial II (REMEDIAL II): RenalGuard system in high-risk patients for contrast-induced acute kidney injury: rationale and design.
Topics: Acetylcysteine; Acute Kidney Injury; Biomarkers; Chi-Square Distribution; Chronic Disease; Contrast | 2011 |
Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury.
Topics: Acetylcysteine; Acute Kidney Injury; Aged; Aged, 80 and over; Carbonates; Contrast Media; Female; Fl | 2011 |
Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury.
Topics: Acetylcysteine; Acute Kidney Injury; Aged; Aged, 80 and over; Carbonates; Contrast Media; Female; Fl | 2011 |
Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury.
Topics: Acetylcysteine; Acute Kidney Injury; Aged; Aged, 80 and over; Carbonates; Contrast Media; Female; Fl | 2011 |
Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury.
Topics: Acetylcysteine; Acute Kidney Injury; Aged; Aged, 80 and over; Carbonates; Contrast Media; Female; Fl | 2011 |
Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury.
Topics: Acetylcysteine; Acute Kidney Injury; Aged; Aged, 80 and over; Carbonates; Contrast Media; Female; Fl | 2011 |
Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury.
Topics: Acetylcysteine; Acute Kidney Injury; Aged; Aged, 80 and over; Carbonates; Contrast Media; Female; Fl | 2011 |
Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury.
Topics: Acetylcysteine; Acute Kidney Injury; Aged; Aged, 80 and over; Carbonates; Contrast Media; Female; Fl | 2011 |
Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury.
Topics: Acetylcysteine; Acute Kidney Injury; Aged; Aged, 80 and over; Carbonates; Contrast Media; Female; Fl | 2011 |
Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury.
Topics: Acetylcysteine; Acute Kidney Injury; Aged; Aged, 80 and over; Carbonates; Contrast Media; Female; Fl | 2011 |
Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury.
Topics: Acetylcysteine; Acute Kidney Injury; Aged; Aged, 80 and over; Carbonates; Contrast Media; Female; Fl | 2011 |
Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury.
Topics: Acetylcysteine; Acute Kidney Injury; Aged; Aged, 80 and over; Carbonates; Contrast Media; Female; Fl | 2011 |
Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury.
Topics: Acetylcysteine; Acute Kidney Injury; Aged; Aged, 80 and over; Carbonates; Contrast Media; Female; Fl | 2011 |
Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury.
Topics: Acetylcysteine; Acute Kidney Injury; Aged; Aged, 80 and over; Carbonates; Contrast Media; Female; Fl | 2011 |
Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury.
Topics: Acetylcysteine; Acute Kidney Injury; Aged; Aged, 80 and over; Carbonates; Contrast Media; Female; Fl | 2011 |
Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury.
Topics: Acetylcysteine; Acute Kidney Injury; Aged; Aged, 80 and over; Carbonates; Contrast Media; Female; Fl | 2011 |
Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury.
Topics: Acetylcysteine; Acute Kidney Injury; Aged; Aged, 80 and over; Carbonates; Contrast Media; Female; Fl | 2011 |
Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ben | 2012 |
The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance.
Topics: Aged; Creatinine; Diuresis; Diuretics; Dose-Response Relationship, Drug; Double-Blind Method; Drug R | 2007 |
Hypertonic saline solution for renal failure prevention in patients with decompensated heart failure.
Topics: Biomarkers; Cardiotonic Agents; Creatinine; Diuretics; Dobutamine; Female; Furosemide; Heart Failure | 2007 |
Does furosemide prevent renal dysfunction in high-risk cardiac surgical patients? Results of a double-blinded prospective randomised trial.
Topics: Aged; Aged, 80 and over; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Creatinine; Diuretics; | 2008 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.
Topics: Aged; Chronic Disease; Contrast Media; Creatinine; Female; Fluid Therapy; Furosemide; Humans; Hypoto | 1994 |
The kidney and hypertension.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Creatinine; Furosemide; Hemodynamics; Humans; Hyp | 1997 |
Effect of lacidipine, a dihydropyridine calcium antagonist on renal function of hypertensive patients with renal insufficiency.
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydro | 1997 |
Evaluation of the safety and efficacy of telmisartan and enalapril, with the potential addition of frusemide, in moderate-renal failure patients with mild-to-moderate hypertension.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Diuret | 2001 |
25 other studies available for furosemide and Kidney Failure
| Article | Year |
|---|---|
WNK4 limits distal calcium losses following acute furosemide treatment.
Topics: Animals; Calcium Channels; Calcium, Dietary; Diuretics; Furosemide; Kidney Tubules, Proximal; Male; | 2019 |
Efficacy and safety of intermittent vs continuous furosemide for heart failure concomitant renal dysfunction: A protocol for systematic review and meta-analysis.
Topics: Drug Administration Schedule; Furosemide; Heart Failure; Humans; Meta-Analysis as Topic; Randomized | 2021 |
Response to a Randomized Trial on Mannitol Use During Partial Nephrectomy.
Topics: Databases, Factual; Diuretics, Osmotic; Furosemide; Humans; Mannitol; Nephrectomy; Practice Patterns | 2021 |
Limited transthoracic echocardiogram: "This is how I do it".
Topics: Adult; Aged; Crystalloid Solutions; Diuretics; Echocardiography; Furosemide; Heart Failure; Humans; | 2017 |
Tolvaptan alleviates excessive fluid retention of nephrotic diabetic renal failure unresponsive to furosemide.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diabetic Nephropathies; Drug Resistan | 2018 |
[Furosemide bolus in acute heart failure].
Topics: Diuretics; Female; Furosemide; Heart Failure; Humans; Male; Renal Insufficiency | 2014 |
Prevention of Contrast-Induced Renal Failure for the Interventional Cardiologist.
Topics: Cardiac Catheterization; Cardiac Surgical Procedures; Cardiologists; Contrast Media; Creatinine; Fur | 2016 |
Predictors of "worsening renal function" in patients hospitalized in internal medicine department.
Topics: Aged; Creatinine; Diuretics; Female; Furosemide; Hospital Departments; Hospitals, Public; Humans; Hy | 2009 |
Rapid oral desensitization to furosemide.
Topics: Administration, Oral; Adult; Desensitization, Immunologic; Drug Hypersensitivity; Female; Furosemide | 2009 |
Cardiovascular collapse following povidone-iodine wash.
Topics: Acidosis; Aged; Anti-Infective Agents, Local; Anticonvulsants; Diuretics; Fluid Therapy; Follow-Up S | 2011 |
[Unauthorized medicine leads to an authorized complained].
Topics: Animals; Clinical Competence; Diuretics; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Furos | 2011 |
Ultrasound evaluation of the inferior vena cava collapsibility index in congestive heart failure patients treated with intravenous diuretics: new insights about its relationship with renal function: an observational study.
Topics: Aged; Cardiac Output, Low; Cohort Studies; Diuretics; Echocardiography; Female; Furosemide; Heart Fa | 2012 |
Clinical experience with low-dose continuous infusion of furosemide in acute heart failure: assessment of efficacy and safety.
Topics: Acute Kidney Injury; Adult; Aged; Cohort Studies; Diuretics; Female; Furosemide; Heart Failure; Hear | 2012 |
[Loop diuretics improves diuresis, but not renal function in the intensive care patient with acute renal failure].
Topics: Acute Disease; Diuresis; Furosemide; Humans; Renal Insufficiency; Sodium Potassium Chloride Symporte | 2012 |
[No evidence for renal protective effect of loop diuretics for patients having oliguria].
Topics: Acute Kidney Injury; Critical Illness; Diuresis; Evidence-Based Medicine; Fluid Therapy; Furosemide; | 2012 |
Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population.
Topics: Acute Disease; Aged; Aged, 80 and over; Benzazepines; Comparative Effectiveness Research; Creatinine | 2013 |
Role of 5-HT3 and 5-HT2C receptors located within the medial amygdala in the control of salt intake in sodium-depleted rats.
Topics: Amygdala; Analysis of Variance; Animals; Avoidance Learning; Behavior, Animal; Biguanides; Dose-Resp | 2006 |
A veno-caliceal fistula related to ureteric stricture in a kidney allograft masquerading as renal failure.
Topics: Contrast Media; Diagnosis, Differential; Diuretics; False Negative Reactions; Furosemide; Humans; Ki | 2007 |
Prevalence, predictors and prognostic value of acute impairment in renal function during intensive unloading therapy in a community population hospitalized for decompensated heart failure.
Topics: Aged; Aged, 80 and over; Diuretics; Furosemide; Heart Failure; Hospitals, Community; Humans; Nitropr | 2007 |
Reversible acute fetal renal failure due to maternal exposure to angiotensin receptor blocker.
Topics: Angiotensin II Type 1 Receptor Blockers; Diuretics; Female; Fetal Diseases; Furosemide; Gestational | 2008 |
Prevention of nephrotoxicity induced by radiocontrast agents.
Topics: Contrast Media; Furosemide; Humans; Mannitol; Renal Insufficiency; Sodium Chloride | 1994 |
Protective effects of enalaprilat against postischemic renal failure.
Topics: Analysis of Variance; Animals; Blood Urea Nitrogen; Creatinine; Dogs; Enalaprilat; Furosemide; Ische | 1993 |
Optimally managing fluid overload in intensive care.
Topics: Critical Care; Diuretics; Furosemide; Humans; Intensive Care Units; Pulmonary Edema; Renal Insuffici | 1997 |
Pharmacoeconomic comparison of an albumin-furosemide complex versus sequential therapy for renal insufficiency.
Topics: Acute Disease; Combined Modality Therapy; Costs and Cost Analysis; Dialysis; Diuretics; Furosemide; | 1999 |
Are screening serum creatinine levels necessary prior to outpatient CT examinations?
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Ch | 2000 |